Healthcare >> CEO Interviews >> February 4, 2002
HARRY A. DUGGER, III is the President and CEO of Flemington
Pharmaceutical Corp. Dr. Dugger was the founder of Flemington
Pharmaceutical Corp. and the inventor of the lingual spray and bite
capsule technology, which the company is developing and marketing as
Immediate-Immediate Release (I2R)'. Dr. Dugger received his PhD from the
University of Michigan and was an NIH Postdoctoral Fellow at the
University Of Zurich working on the chemical structure of the colors in
red beets and on pseudo-aromatic compounds. He joined Sandoz
Pharmaceuticals in the USA in 1964, where he was responsible for drug
development primarily in the areas of biopharmaceuticals and drug
metabolism. In 1980 he resigned to join Baurs-Krey Associates in New
York, and in 1982 he founded Pharmaconsult, the precursor to Flemington.
Through Pharmaconsult Dr. Dugger advised clients on all aspects of drug
development, including but not limited to manufacturing of drug
substances and drug products (cGMP), toxicity studies, clinical trails,
filing of ANDAs, INDs, NDAs as well as co-founding LAB Inc. in the US to
market the clinical services of LAB GmbH (Germany) to US-based
pharmaceutical companies. Since 1996 Dr. Dugger has spent much of his
time in developing a number of I2R formulations and running studies to
demonstrate their utility. Profile
overview of what you're doing at the present time?
Dr. Dugger: Flemington Pharmaceutical Corp. (FPC) started in 1982 as
